Vontobel continues multi-boutique expansion in North America
NEW YORK--(BUSINESS WIRE)--With growing demand from US and Canadian investors for systematic and fundamental investing, Vontobel has made available...
Alex
Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab...
AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug Designation in Korea for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
NEW YORK & SEOUL, South Korea--(BUSINESS WIRE)--#BTD--AnHeart Therapeutics and NewG Lab Therapeutics, a subsidiary of NewG Lab Pharma, announced that...
Bacardi Announces New Leadership for Its Global Travel Retail Business
HAMILTON, Bermuda--(BUSINESS WIRE)--#BacardiLife--Bacardi announces a change at the top of its global travel retail business (GTR), effective January 2023. The...
Vista Gold Corp. Provides Update on Strategic Process
DENVER--(BUSINESS WIRE)--Vista Gold Corp. (NYSE American and TSX: VGZ) (“Vista” or the “Company”) today announced the following update regarding the...
LESSENGERS Demonstrates 800G QSFP-DD and 400G QSFP112 Optical Transceivers
BASEL, Switzerland--(BUSINESS WIRE)--LESSENGERS Inc. (“LESSENGERS”), an innovative optical interconnect solution provider, announced today, a live demonstration of polymer-wired 800G QSFP-DD...
India Over The Counter Drug Market to Grow at 7.85% Through 2028 – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "India Over The Counter Drug Market, By Product Type, By Route of Administration, By Dosage Form, By Distribution...
J.P. Morgan to Acquire Renovite Technologies, Inc.
Acquisition of cloud-native payments technology firm to modernize infrastructure and create greater flexibility for the firm’s merchant acquiring capabilities globally...
Announcement for “Innovation for Cool Earth Forum 9th Annual Meeting (ICEF2022)”
The international conference to discuss innovation, the key to solving global warming with experts from industry, academia, and government from...
Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region
Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights....
Base Business Solutions and Uniphore Partner to Bring Emerging Technology to Vietnam’s CX Industry
The partnership will help boost contact center employee morale and provide superior customer experiences using Conversational AI and Automation HO...
Chery Is Accompanied With Love at the Mid-Autumn Festival
WUHU, China--(BUSINESS WIRE)--China celebrates the Mid-Autumn Festival on September 10. On this day, all Chinese families will partake in eating...
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of...
DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer
Extended follow-up data from phase 1/2 trial of DS-7300 in patients with metastatic lung, prostate or esophageal cancer to be...
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trial Additional poster presentations...
